Paper - WANFANG MED ONLINE

You Position: Home > Paper

New progress in research of Th17 cells and related cytokines in inflammatory bowel disease

( views:20, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 24

DOI:: 10.11569/wcjd.v29.i24.1402

Key Word:: 炎症性肠病;Th17细胞;肠道免疫;IL-17;IL-23;IL-10;IL-22

Abstract：炎症性肠病(inflammatory bowel disease,IBD)是一种慢性非特异性肠道炎症疾病,是一种免疫性疾病,目前尚无根治疗法,肠道免疫是炎症性肠病的研究重点,本文就Th17细胞及其相关细胞因子在炎症性肠病中的新研究进行综述,包括炎症性肠病病因、与适应性免疫的关系、与Th17细胞的关系,Th17细胞介绍、其相关细胞因子的介绍,和它们在IBD的研究状况,最后展望Th17细胞与IBD的未来研究方向.

Reference

[1]Mingming,Sun,Wei,Wu,Liang,Chen,etc.Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis.[J].2018,9(1).
[2]Yi-Zhen Zhang,Yong-Yu Li.Inflammatory bowel disease:Pathogenesis[J].2014,(1).
[3]Yujin Liu,Yalan Dong,Xiwen Zhu,etc.MiR-155 inhibition ameliorates 2, 4, 6-Trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis in rat via influencing the differentiation of Th17 cells by Jarid2[J].2018,64.
[4]Neurath Markus F..Cytokines in inflammatory bowel disease[J].2014,14(5).
[5]Ganji‐Arjenaki Mahboube,Rafieian‐Kopaei Mahmoud.Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review[J].2018,233(3).
[6]Sugimoto K,Andoh A,Ogawa A,etc.IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis.[J].2008,118(2).
[7]Sarah C,Davies,Tran M,Nguyen,Claire E,Parker,etc.Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn’s disease.[J].2019,12.
[8]Monteleone,I.,Sarra,M.,Monteleone,G.,etc.Th17-related cytokines in inflammatory bowel diseases: Friends or foes?[J].2012,12(5).
[9]Cai, Jun,Zhang, Zhongtao.An Analysis of IL-10/IL-10R Genetic Factors Related to Risk of Colon Cancer and Inflammatory Bowel Disease in a Han Chinese Population[J].2016,62(6).
[10]Anyan Xie,René J. Robles,Samiran Mukherjee,etc.HIF-1α-induced xenobiotic transporters promote Th17 responses in Crohn's disease[J].2018,94.
[11]Latella Giovanni,Viscido Angelo.Controversial Contribution of Th17/IL-17 Toward the Immune Response in Intestinal Fibrosis[J].2020,65(5).
[12]Yamada Akihiro,Wang Jingzhou,Komaki Yuga,etc.Systematic review with meta‐analysis: risk of new onset IBD with the use of anti‐interleukin‐17 agents[J].2019,50(4).
[13]Neumann, Christian,Scheffold, Alexander,Rutz, Sascha.Functions and regulation of T cell-derived interleukin-10[J].2019,44.
[14]Lei, Zhu,Tingting, Shi,Chengdi, Zhong,etc.IL-10 and IL-10 Receptor Mutations in Very Early Onset Inflammatory Bowel Disease.[J].2017,10(2).
[15]Aito Ueno,Louisa Jeffery,Taku Kobayashi,etc.Th17 plasticity and its relevance to inflammatory bowel disease[J].2018,87.
[16]Markus F,Neurath.IL-23 in inflammatory bowel diseases and colon cancer.[J].2018.
[17]Gu,C.,Wu,L.,Li,X..IL-17 family: Cytokines, receptors and signaling[J].2013,64(2).
[18]Hiroshi,Nakase.Treatment of inflammatory bowel disease from the immunological perspective.[J].2020.
[19]McCombie,A.M.,Mulder,R.T.,Gearry,R.B..How IBD patients cope with IBD: A systematic review[J].2013,7(2).
[20]Zahra Omidian,Rizwan Ahmed,Adebola Giwa,etc.IL-17 and limits of success[J].2019,339.
[21]Catana, Cristina-Sorina,Neagoe, Ioana Berindan,Cozma, Vasile,etc.Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease[J].2015,21(19).
[22]Mizoguchi,A..Healing of intestinal inflammation by IL-22[J].2012,18(9).
[23]Neurath, Markus F..Targeting immune cell circuits and trafficking in inflammatory bowel disease[J].2019,20(8).
[24]Chen, Mei Lan,Sundrud, Mark S..Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases[J].2016,22(5).
[25]Yasuda, Keiko,Takeuchi, Yusuke,Hirota, Keiji.The pathogenicity of Th17 cells in autoimmune diseases[J].2019,41(3).
[26]Jiang Wenyu,Su Jiewen,Zhang Xiaofei,etc.Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease[J].2014,63(11).
[27]Megan Hohenberger,Leah A. Cardwell,Elias Oussedik,etc.Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease[J].2018,29(1).
[28]Castro-Dopico, Tomas,Colombel, Jean-Frederic,Mehandru, Saurabh.Targeting B cells for inflammatory bowel disease treatment: back to the future[J].2020,55.
[29]Perez Laura Garcia,Kempski Jan,McGee Heather M.,etc.TGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer[J].2020,11(1).
[30]Yang,J.,Sundrud,M.S.,Skepner,J.,etc.Targeting Th17 cells in autoimmune diseases[J].2014,35(10).
[31]Moschen, Alexander R.,Tilg, Herbert,Raine, Tim.IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting[J].2019,16(3).
[32]Atsushi Mizoguchi,Arisa Yano,Hidetomo Himuro,etc.Clinical importance of IL-22 cascade in IBD[J].2018,53(4).
[33]Geremia,A.,Biancheri,P.,Allan,P.,etc.Innate and adaptive immunity in inflammatory bowel disease[J].2014,13(1).
[34]Florholmen J,Goll R,Olsen T,etc.TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation.[J].2011,56(3).
[35]Wanda Niedbala,Xiao‐qing Wei,Beilei Cai,etc.IL‐35 is a novel cytokine with therapeutic effects against collagen‐induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells[J].2007,37(11).